Celcuity: What's Happening With CELC Stock?

1. CELC surged 3x following positive Phase 3 trial results for gedatolisib. 2. Gedatolisib’s sales potential exceeds $2 billion; FDA approval is planned for Q4 2025. 3. Upcoming capital offerings aim to support R&D amid significant cash burn. 4. Risks include FDA approval hurdles and an intense competitive oncology landscape. 5. Current optimism may be tempered by potential regulatory setbacks, impacting stock valuation.